In conclusion, we identified ARS2 as a new and important transcription factor that promotes the stem cell identity of GSCs through MAGL-mediated signaling and further showed that blockade of MAGL provides a promising therapeutic avenue for treating GBM. Here, MGLL is linked to glioblastoma.